Patent Grant
10959967
The invention relates to effervescent oral care compositions comprising a basic amino acid.
Effervescent powders and tablets are well known in the art, and generally “fizz” when added to water. Such effervescent materials have been utilized in various arts for multiple purposes. For example, ALKA-SELTZER from Bayer Corporation may be used to deliver any number of medicaments for various indications, such as headache, indigestion, gas, stomach cramps, and heartburn. The use of effervescent products to orally deliver medicaments orally is advantageous in that there is no need to swallow capsules or capsules, which is a problem for the elderly and young children. Effervescent products may also include flavorings, which can mask the taste of many medicaments. Some studies have also indicated that the use of effervescent powders in the administration of medicaments also results in enhanced absorption of actives.
Effervescence is usually produced by the reaction of an acid with a carbonate salt, to release carbon dioxide. For example, citric acid may react with sodium bicarbonate to form carbon dioxide, water and sodium citrate. Considering the benefits of effervescent products in the delivery of medicaments, it is desirable to develop improvements in such formulations. As existing effervescent formulations may contribute to dental decay, it is desirable to develop effervescent compositions which do not only avoid decay, but may treat or reverse such effects, and treat disorders of the mouth.
The present invention includes effervescent compositions comprising a physiologically acceptable salt of a basic amino acid, an acid source, and a soluble carbonate salt, wherein when the composition is dissolved in a solvent, e.g., water, carbon dioxide is released, and the amino acid salt is substantially solubilized.
By “soluble carbonate salt” is meant any salt formed by carbonic acid or dissolved carbon dioxide which is sufficiently soluble to react with the acid in the concentrations provided. In aqueous solution, the carbonate ion, bicarbonate ion, carbon dioxide, and carbonic acid form a dynamic equilibrium. The term “carbonate” as used herein thus generally encompasses the bicarbonate (HCO3−) and carbonate (CO32−) forms and mixtures thereof, unless otherwise specified. Soluble carbonate salts thus include, e.g., potassium carbonate, potassium bicarbonate, sodium carbonate, and sodium bicarbonate. The present invention includes solid effervescent forms, such as tablets, powders and granulates, as well as effervescent compositions comprising single tube non-aqueous or low water toothpastes and alternatively dual tube or sequestered compositions, wherein the acid and carbonate are kept separate until use.
The invention thus provides in one embodiment, an effervescent product (Composition 1.0) comprising a basic amino acid in free or physiologically acceptable salt form, an acid source, and a soluble carbonate salt.
In some embodiments, the basic amino acid may be in carbonate or bicarbonate salt form, in which case it can also serve as all or part of the soluble carbonate salt component of the invention.
The invention further includes the following Compositions:
Composition 1.28 wherein either the acid source or the soluble carbonate salt is encapsulated such that upon use the encapsulate will break and the acid source and soluble carbonate salt will react to release carbon dioxide. In another embodiment of the present invention, Composition 2.0 is provided comprising any of compositions 1.0-1.26 in the form of a tablet.
The present invention also includes the following compositions:
2.3 Of composition 2.0-2.2 further comprising a binder.
The present invention also encompasses method 3.0, a method to (i) reduce or inhibit formation of dental caries, (ii) reduce, repair or inhibit pre-carious lesions of the enamel, e.g., as detected by quantitative light-induced fluorescence (QLF) or electrical conductance measurement (ECM), (iii) reduce or inhibit demineralization and promote remineralization of the teeth, (iv) reduce hypersensitivity of the teeth, (v) reduce or inhibit gingivitis, (vi) promote healing of sores or cuts in the mouth, (vii) reduce levels of acid producing bacteria, (viii) to increase relative levels of arginolytic bacteria, (ix) inhibit microbial biofilm formation in the oral cavity, (x) raise and/or maintain plaque pH at levels of at least pH 5.5, (xi) reduce plaque accumulation, (xii) clean the teeth and oral cavity, (xiii) immunize the teeth against cariogenic bacteria, (xiv) reduce erosion, (xv) enhance systemic health, and/or (xvi) treat or inhibit dry mouth, comprising applying a Composition of the Invention to the oral cavity, e.g., by applying a Composition of the Invention to the oral cavity of a patient in need thereof.
The invention also comprises the following methods:
Other embodiments of the present invention will be apparent to one of skill in the art.
Effervescence generally results from the reaction of an acid and a carbonate in water to produce carbon dioxide. The acid may, for example, be selected from organic acids such as citric, malic, tartaric, adipic, and fumaric acid and mixtures thereof. Carbonates include carbonates of amino acids, e.g., arginine bicarbonate, as well as alkali carbonates, e.g., such as sodium bicarbonate, potassium bicarbonate, sodium carbonate, and potassium bicarbonate. It has been surprisingly found that basic amino acids salts may not only be used as a basic salt, but such basic amino acid salts also impart benefits to the oral cavity.
Without intending to be bound by a particular theory, it is believed that basic amino acids in the oral cavity are metabolized by certain types of bacteria, e.g., S. sanguis which are not cariogenic and which compete with cariogenic bacteria such as S. mutans, for position on the teeth and in the oral cavity. The arginolytic bacteria can use arginine and other basic amino acids to produce ammonia, thereby raising the pH of their environment, while cariogenic bacteria metabolize sugar to produce lactic acid, which tends to lower the plaque pH and demineralize the teeth, ultimately leading to cavities. It is believed that use of a Composition of the Invention may lead to a relative increase in the arginolytic bacteria and a relative decrease in the cariogenic bacteria, resulting in a higher plaque pH.
The basic amino acids which can be used in the compositions and methods of the invention include not only naturally occurring basic amino acids, such as arginine, lysine, and histidine, but also any basic amino acids having a carboxyl group and an amino group in the molecule, which are water-soluble and provide an aqueous solution with a pH of about 7 or greater. Accordingly, basic amino acids include, but are not limited to, arginine, lysine, citrullene, ornithine, creatine, histidine, diaminobutanoic acid, diaminoproprionic acid, salts thereof or combinations thereof. In a particular embodiment, the basic amino acids are selected from arginine, citrullene, and ornithine, preferably, arginine, for example, 1-arginine.
The compositions of the invention are used in the mouth, and optionally may be ingested, and so salts for use in the present invention should be safe for such use, in the amounts and concentrations provided. Suitable salts include salts known in the art to be pharmaceutically acceptable salts are generally considered to be physiologically acceptable in the amounts and concentrations provided. Physiologically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic acids or bases, for example acid addition salts formed by acids which form a physiological acceptable anion, e.g., hydrochloride or bromide salt, and base addition salts formed by bases which form a physiologically acceptable cation, for example those derived from alkali metals such as potassium and sodium or alkaline earth metals such as calcium and magnesium. Physiologically acceptable salts may be obtained using standard procedures known in the art, for example, by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. A preferred salt is a bicarbonate, e.g., arginine bicarbonate.
In various embodiments, the basic amino acid is present in an amount of about 0.5 wt. % to about 50 wt. % of the total composition weight, about 1 wt. % to about 10 wt. % of the total composition weight, for example about 1.5 wt. %, about 3.75 wt. %, about 5 wt. %, or about 7.5 wt. % of the total composition weight.
If the effervescent powders of the present invention may optionally include fluoride, or a fluoride ion source e.g., when formulated to be dissolved in a solvent to be used as a mouthwash. A wide variety of fluoride ion-yielding materials can be employed as sources of soluble fluoride in the present compositions. Examples of suitable fluoride ion-yielding materials are found in U.S. Pat. No. 3,535,421, to Briner et al.; U.S. Pat. No. 4,885,155, to Parran, Jr. et al. and U.S. Pat. No. 3,678,154, to Widder et al., incorporated herein by reference. Representative fluoride ion sources include, but are not limited to, stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, ammonium fluoride, and combinations thereof. In certain embodiments the fluoride ion source includes stannous fluoride, sodium fluoride, sodium monofluorophosphate as well as mixtures thereof. Thus, such effervescence powders may also contain a source of fluoride ions or fluorine-providing ingredient in amounts sufficient to supply about 25 ppm to about 25,000 ppm of fluoride ions, generally at least about 500 ppm, e.g., about 500 to about 2000 ppm, e.g., about 1000 to about 1600 ppm, e.g. about 1450 ppm. Fluoride ion sources may be added to the compositions of the invention at a level of about 0.01 wt. % to about 10 wt. % in one embodiment or about 0.03 wt. % to about 5 wt. %, and in another embodiment about 0.1 wt. % about 1 wt. % by weight of the composition in another embodiment. Weights of fluoride salts to provide the appropriate level of fluoride ion will obviously vary based on the weight of the counter ion in the salt.
The effervescent powders of the present invention may also comprise antiseptics and antimicrobial compounds, e.g., triclosan, herbal extracts and essential oils (e.g., rosemary extract, thymol, menthol, eucalyptol, methyl salicylate), bisguanide antiseptics (e.g., chlorhexidine, alexidine or octenidine), quaternary ammonium compounds (e.g., cetylpyridinium chloride), phenolic antiseptics, hexetidine, povidone iodine, delmopinol, salifluor, metal ions (e.g., zinc salts, for example, zinc citrate), sanguinarine, propolis, and antibiotics. Such antiseptics and antimicrobial compounds are desirable when the effervescent powers of the present invention are formulated to dissolve in a solvent to form a mouthwash.
The effervescent powders of the present invention may also include one or more medicaments or other active, e.g., acetylsalicylic acid, acetaminophen, vitamins, and medications which are psychotropic, anti-hypertensitive, anti-seizure, amphetamine, anti-microbial, antibiotic, anti-viral, anti-retroviral, anti-fungal, anti-depressant, stimulants, anti-histamine, anti-anxiety, tricyclics, tranquilizers, benzodiazepines, hypnotics, mood stabilizers, codeine, selective serotonin reuptake inhibitors, anti-allergy, phenothiazine, chemotherapeutics, amines, monoamine oxidase inhibitors, anti-carcinogens, analgesics, muscle relaxants, ergot preparations, anti-cholinergic, anti-inflammatory, anti-gout preparations, soporific, hormonal preparations, appetite suppressants, analgesics, muscle relaxants, and opioids
The effervescent powders of the present invention may also include one or more flavoring agents. Flavoring agents which are used in the practice of the present invention include, but are not limited to, essential oils as well as various flavoring aldehydes, esters, alcohols, and similar materials. Examples of the essential oils include oils of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, marjoram, cinnamon, lemon, lime, grapefruit, and orange. Also useful are such chemicals as menthol, carvone, and anethole. Certain embodiments employ the oils of peppermint and spearmint. Various acids and bases to produce effervescence may also be flavoring agents, such as citric acid and malic acid.
The flavoring agent is incorporated in the oral composition at a concentration of about 0.1 to about 5% by weight and about 0.5 to about 1.5% by weight. The dosage of flavoring agent in the individual oral care composition dosage (i.e., a single dose) is about 0.001 to 0.05% by weight and in another embodiment about 0.005 to 0.015% by weight
The effervescent powers of the present invention may be compressed into a tablet form, e.g., to create a single dose format to be added to a solvent. Methods of producing tablets, and general tablet compositions are well known in the art. Tablets generally contain a binder, which are known by those of skill in the art. Preferably, the binders are soluble and include, e.g., dextrose, sorbitol, xylitol, and lactose. Preferably, the amount of binder allows for the tablet to be hard enough to handle, soft enough to disintegrate when introduced into a solvent, and dry enough to be stable.
Tablets may also comprise a lubricant to aid in expulsion of the table from a press. Such lubricants are known by those of skill in the art, and include magnesium stearate, sodium benzoate, polyethylene glycol, and adipic acid.
In one embodiment of the present invention, an effervescent tablet may be placed directly into the mouth to dissolve and form a mouth wash.
A powder composition is formulated in accordance with the following:
Arginine bicarbonate—50% wt.
Citric Acid—50% wt.
A powder composition is formulated in accordance with the following:
Arginine bicarbonate—40% wt.
Citric Acid—50% wt.
Sodium carbonate—10% wt.
0.5 grams of acetylsalicylic acid is added to 10 grams of the compositions of Examples 1 or 2, and compressed into a tablet.
A tablet prepared in accordance with EXAMPLE 2 is allowed to dissolve and effervesce in 20 ml of cold water. The tablet disintegrates within 2 minutes and is consumed by a person.
Powder compositions are prepared according to the formulations listed in Table 1.
10%
38%
The powders of EXAMPLE 5 are compressed into tablets 3 grams each, with a diameter of 20 mm.
A tablet of EXAMPLE 7 is dissolved in from about 15-30 ml of water and allowed to effervesce and dissolve. Insoluble particles are allowed to precipitate. A person agitates the solution to suspend insoluble particles to form a mouthwash, and then takes the solution into the oral cavity for 30 seconds before expelling the solution. The person repeats the procedure daily for one month and finds the mouthwash reduces hypersensitivity of the teeth, and treats dry mouth.
A powder composition having the following formulation is prepared:
Potassium carbonate—20.5%
Citric acid—45.5%
Flavor, color and solvent—3%
SLS—0.5%
Sweetener—0.5%
Basic Amino Acid—30%
The compositions of EXAMPLE 8 are compressed into a tablets weighing 3 grams each.
The tablets of EXAMPLE 8 are taken into a person's mouth and allowed to effervesce with liquid, e.g., saliva, in the oral cavity. The person swishes the resultant solution in the mouth for 30 seconds and then expels the solution from the oral cavity.
An effervescent dual dentifrice composition having the following formulation is prepared:
Components A and B are packaged so that the phosphoric acid in B does not react with the arginine bicarbonate in A prior to use. When the product is dispensed and used, A and B combined, and carbon dioxide is released.
This application claims the benefit of U.S. Patent Application Ser. No. 61/027,430 filed Feb. 8, 2008, the contents of which are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US2009/033299 | 2/6/2009 | WO | 00 | 8/6/2010 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2009/100272 | 8/13/2009 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3535421 | Briner et al. | Oct 1970 | A |
| 3678154 | Widder et al. | Jul 1972 | A |
| 3772431 | Mlkvy | Nov 1973 | A |
| 3903255 | Gusman et al. | Sep 1975 | A |
| 3925543 | Donohue | Dec 1975 | A |
| 3932605 | Vit | Jan 1976 | A |
| 3932608 | Anderson et al. | Jan 1976 | A |
| 3943241 | Anderson et al. | Mar 1976 | A |
| 3988434 | Schole et al. | Oct 1976 | A |
| 4011309 | Lutz | Mar 1977 | A |
| 4022880 | Vinson et al. | May 1977 | A |
| 4025616 | Haefele | May 1977 | A |
| 4042680 | Muhler et al. | Aug 1977 | A |
| 4064138 | Saari et al. | Dec 1977 | A |
| 4100269 | Pader | Jul 1978 | A |
| 4108979 | Muhler et al. | Aug 1978 | A |
| 4108981 | Muhler et al. | Aug 1978 | A |
| 4146607 | Ritchey | Mar 1979 | A |
| 4154813 | Kleinberg | May 1979 | A |
| 4160821 | Sipos | Jul 1979 | A |
| 4211341 | Weyn | Jul 1980 | A |
| 4216961 | Curtis et al. | Jul 1980 | A |
| 4225579 | Kleinberg | Sep 1980 | A |
| 4259316 | Nakashima et al. | Mar 1981 | A |
| 4267164 | Yeh | May 1981 | A |
| 4269822 | Pellico et al. | May 1981 | A |
| 4305928 | Harvey | Dec 1981 | A |
| 4335102 | Nakashima et al. | Jun 1982 | A |
| 4339432 | Ritchey et al. | Jul 1982 | A |
| RE31181 | Kleinberg et al. | Mar 1983 | E |
| 4466954 | Ichikawa et al. | Aug 1984 | A |
| 4487757 | Kiozpeoplou | Dec 1984 | A |
| 4528181 | Morton et al. | Jul 1985 | A |
| 4532124 | Pearce | Jul 1985 | A |
| 4538990 | Pashley | Sep 1985 | A |
| 4645662 | Nakashima et al. | Feb 1987 | A |
| 4656031 | Lane et al. | Apr 1987 | A |
| 4725576 | Pollock et al. | Feb 1988 | A |
| 4885155 | Parran et al. | Dec 1989 | A |
| 4997640 | Bird et al. | Mar 1991 | A |
| 5096700 | Siebel et al. | Mar 1992 | A |
| 5286480 | Boggs et al. | Aug 1994 | A |
| 5334617 | Ulrich et al. | Dec 1994 | A |
| 5370865 | Yamagishi et al. | Dec 1994 | A |
| 5693795 | Friedman et al. | Jun 1997 | A |
| 5747004 | Giani | May 1998 | A |
| 5762911 | Kleinberg et al. | Jun 1998 | A |
| 5817294 | Arnold | Oct 1998 | A |
| 5906811 | Hersh | May 1999 | A |
| 5922346 | Hersh | Jul 1999 | A |
| 5925378 | Carnazzo | Jul 1999 | A |
| 5997301 | Linden | Dec 1999 | A |
| 6217851 | Kleinberg | Apr 2001 | B1 |
| 6436370 | Kleinberg et al. | Aug 2002 | B1 |
| 6488961 | Robinson et al. | Dec 2002 | B1 |
| 6524588 | Kleinberg et al. | Feb 2003 | B1 |
| 6805883 | Chevaus et al. | Oct 2004 | B2 |
| 7815897 | Wehling | Oct 2010 | B1 |
| 20020081360 | Burgard et al. | Jun 2002 | A1 |
| 20020127184 | Selim | Sep 2002 | A1 |
| 20020131987 | Carnazzo | Sep 2002 | A1 |
| 20030099760 | Okai | May 2003 | A1 |
| 20030170301 | Wehling | Sep 2003 | A1 |
| 20070154863 | Cai et al. | Jul 2007 | A1 |
| 20070184826 | Won-Hyoung et al. | Aug 2007 | A1 |
| Number | Date | Country |
|---|---|---|
| 1266652 | Sep 2000 | CN |
| 101077339 | Nov 2007 | CN |
| 19800812 | Jul 1999 | DE |
| 2786395 | Jun 2000 | FR |
| 1178294 | Jan 1970 | GB |
| 1321419 | Jun 1973 | GB |
| 07-258053 | Oct 1995 | JP |
| H0958053 | Mar 1997 | JP |
| 2001-089337 | Apr 2001 | JP |
| WO 0122917 | Apr 2001 | WO |
| WO 0152803 | Jul 2001 | WO |
| WO 2003026610 | Apr 2003 | WO |
| WO 2005099658 | Oct 2005 | WO |
| WO 2007075408 | Jul 2007 | WO |
| Entry |
|---|
| Machado et al. CaviStat Confection Inhibition of Caries in Posterior Teeth, Abstract, 83rd Session of the American Association for Dental Research, Mar. 21-24, 2007, New Orleans, LA. |
| Chatterjee et al,. Bacterial Acidification and CaviStat Alkalinization of Occlusal Fissure pH, Abstract, 83rd Session of the American Association for Dental Research, Mar. 9-12, 2005, Baltimore, MD. |
| Kleinberg I., A Mixed-Bacteria Ecological Approach to Understanding the Role of the Oral Bacteria in Dental Caries Causation: An Alternative to Streptococcus Mutans and the Specific-Plaque Hypothesis, CRIT. Rev. Oral Biol. Med,. 12(2): 108-125 (2002). |
| Kleinberg I., A New Salvia-Based Anticaries Composition, Dentistry Today, vol. 18, No. 2, Feb. 1999. |
| Acevedo et al., “The Inhibitory effect of an arginine bicarbonate/calcium carbonate (CaviStat)-containing dentifrice on the develpoment of dental caries in Venezuelean school children”, The Journal of clinical Dentistry, 2005, v.16, No. 3,pp. 63-70, ISSN 0895-8831. |
| “Neutraceutics—Symbiotropin Berry Effervescent 40 Packets,” Nutrition Express Website (Oct. 3, 2006). |
| Anonymous, “A Review of Patents on Effervescent Granules,” (http://www.pharmainfo.net/reviews/review-patents-effervescent-granules). |
| Number | Date | Country | |
|---|---|---|---|
| 20100322985 A1 | Dec 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61027430 | Feb 2008 | US |
